Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017


#1021076

35pages

Global Markets Direct

$ 2000

In Stock

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) Pipeline Review, H1 2017, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.

Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngitis (Common Cold) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration and Preclinical stages are 2 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nasopharyngitis (Common Cold) - Overview
Nasopharyngitis (Common Cold) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Nasopharyngitis (Common Cold) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
Charleston Laboratories Inc
Orbis Biosciences Inc
Vernalis Plc
Nasopharyngitis (Common Cold) - Drug Profiles
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLAT-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasopharyngitis (Common Cold) - Dormant Projects
Nasopharyngitis (Common Cold) - Discontinued Products
Nasopharyngitis (Common Cold) - Product Development Milestones
Featured News & Press Releases
Sep 06, 2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Nasopharyngitis (Common Cold), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, H1 2017
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H1 2017
Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H1 2017
Nasopharyngitis (Common Cold) - Dormant Projects, H1 2017
Nasopharyngitis (Common Cold) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017